BR112017019357A2 - sal acetato de buprenorfina e métodos para preparar buprenorfina - Google Patents

sal acetato de buprenorfina e métodos para preparar buprenorfina

Info

Publication number
BR112017019357A2
BR112017019357A2 BR112017019357A BR112017019357A BR112017019357A2 BR 112017019357 A2 BR112017019357 A2 BR 112017019357A2 BR 112017019357 A BR112017019357 A BR 112017019357A BR 112017019357 A BR112017019357 A BR 112017019357A BR 112017019357 A2 BR112017019357 A2 BR 112017019357A2
Authority
BR
Brazil
Prior art keywords
buprenorphine
preparing
methods
acetate salt
acetate salts
Prior art date
Application number
BR112017019357A
Other languages
English (en)
Inventor
Sharma Archana
Wayne Kataisto Erik
Huntley Frederick
Alfred REISCH Helge
Larry STYMIEST Jake
Original Assignee
Rhodes Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodes Tech filed Critical Rhodes Tech
Publication of BR112017019357A2 publication Critical patent/BR112017019357A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

a presente divulgação proporciona sais acetato de buprenorfina e seus anidratos, solvatos, hidratos e formas cristalinas dos mesmos, onde os sais acetato de buprenorfina são essencialmente isentos de impurezas. a divulgação proporciona ainda um método de preparação de sais acetato, base livre de buprenorfina preparada a partir dos sais acetato, outros sais preparados a partir da base livre e composições farmacêuticas dos mesmos essencialmente isentas de impurezas.
BR112017019357A 2015-03-10 2016-03-09 sal acetato de buprenorfina e métodos para preparar buprenorfina BR112017019357A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562131114P 2015-03-10 2015-03-10
PCT/IB2016/051332 WO2016142877A1 (en) 2015-03-10 2016-03-09 Acetate salt of buprenorphine and methods for preparing buprenorphine

Publications (1)

Publication Number Publication Date
BR112017019357A2 true BR112017019357A2 (pt) 2018-06-05

Family

ID=55524412

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019357A BR112017019357A2 (pt) 2015-03-10 2016-03-09 sal acetato de buprenorfina e métodos para preparar buprenorfina

Country Status (19)

Country Link
US (6) US10406152B2 (pt)
EP (1) EP3283490A1 (pt)
JP (2) JP6660399B2 (pt)
KR (2) KR20170137738A (pt)
CN (1) CN107660207B (pt)
AR (1) AR103902A1 (pt)
AU (2) AU2016230750B2 (pt)
BR (1) BR112017019357A2 (pt)
CA (2) CA2977732C (pt)
CO (1) CO2017009130A2 (pt)
EA (1) EA201792014A1 (pt)
IL (1) IL254384A0 (pt)
MA (1) MA45902A (pt)
MX (1) MX2017011606A (pt)
NZ (1) NZ735736A (pt)
PH (1) PH12017501641A1 (pt)
SG (1) SG11201707350TA (pt)
TW (2) TWI699367B (pt)
WO (1) WO2016142877A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3553177B1 (en) 2013-03-15 2020-12-09 The Board of Trustees of the Leland Stanford Junior University Benzylisoquinoline alkaloids (bia) producing microbes, and methods of making and using the same
EP3066207A1 (en) 2013-11-04 2016-09-14 The Board Of Trustees Of The University Of the Leland Stanford Junior University Benzylisoquinoline alkaloid (bia) precursor producing microbes, and methods of making and using the same
CA2977732C (en) 2015-03-10 2021-02-23 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine
EP3292203A4 (en) 2015-05-04 2019-10-09 The Board of Trustees of the Leland Stanford Junior University BENZYL ISOCHINOLIN ALKALOID (BIA) Precursor Producing Microbicides and Method for the Preparation and Use Thereof
GB2555044B (en) 2015-05-08 2021-03-17 Univ Leland Stanford Junior Methods of producing epimerases and benzylisoquinoline alkaloids
EP3529355A4 (en) 2016-10-18 2020-07-08 Antheia, Inc. PROCESSES FOR THE PRODUCTION OF NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS
JP7199417B2 (ja) 2017-08-03 2023-01-05 アンテイア インコーポレイテッド 遺伝子操作されたベンジルイソキノリンアルカロイドエピメラーゼおよびベンジルイソキノリンアルカロイドの生成方法
JP7421804B2 (ja) 2018-05-11 2024-01-25 ▲ユ▼展新藥生技股分有限公司 ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形
WO2023246865A1 (en) * 2022-06-24 2023-12-28 Alar Pharmaceuticals Inc. Stable pharmaceutical composition of buprenorphine and preparation method and use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275638A (en) * 1966-09-27 Chjcoo-
US2191786A (en) 1938-03-18 1940-02-27 C A Miketta Continuous process for making adipic acid
BE466549A (pt) 1945-07-17
US3355486A (en) 1965-01-08 1967-11-28 Fmc Corp Continuous process of synthesizing amino-iminomethane-sulfinic acid
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1312447A (en) 1969-05-14 1973-04-04 Nat Res Dev Method of continuous addition of a component to a chemical or biological system and apparatus therefor
US4217287A (en) 1971-10-06 1980-08-12 Gulf Research & Development Company Epoxidation of alpha-olefins
US3936462A (en) * 1972-05-26 1976-02-03 Sterling Drug Inc. 1,2,3,4,5,6-Hexahydro-1-oxo or hydroxy-3-acyl-2,6-methano-3-benzazocines and corresponding 1-esters thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
GB1520139A (en) 1976-06-08 1978-08-02 Ferranti Ltd Gyroscopic apparatus
US4362870A (en) * 1980-01-16 1982-12-07 Regents Of The University Of Minnesota Selective opioid receptor alkylating agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4830028A (en) 1987-02-10 1989-05-16 R. J. Reynolds Tobacco Company Salts provided from nicotine and organic acid as cigarette additives
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6344211B1 (en) 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
TW452907B (en) 1999-11-22 2001-09-01 Winbond Electronics Corp Testing device and method of positive mobile ion contamination
US6994827B2 (en) 2000-06-03 2006-02-07 Symyx Technologies, Inc. Parallel semicontinuous or continuous reactors
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US7560445B2 (en) 2005-07-06 2009-07-14 Taro Pharmaceuticals North America, Inc. Process for preparing malathion for pharmaceutical use
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
CA2671518C (en) 2006-12-04 2016-06-07 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
JP5384363B2 (ja) 2006-12-11 2014-01-08 アルコン リサーチ， リミテッド 実質的に純粋なフルオレセイン
JP5544544B2 (ja) * 2008-08-05 2014-07-09 株式会社 メドレックス 塩基性薬効成分の脂肪酸塩、安息香酸塩を含有する外用剤とその製造方法
US8492547B2 (en) * 2009-07-09 2013-07-23 Mallinckrodt Llc Method for the enrichment of buprenorphine using chromatographic techniques
EP2621496B2 (en) * 2010-09-30 2018-12-12 AstraZeneca AB Crystalline naloxol-peg conjugate
AR089201A1 (es) * 2011-12-12 2014-08-06 Lohmann Therapie Syst Lts Sistema de suministro transdermico
EP3485880A1 (en) 2012-04-17 2019-05-22 Purdue Pharma LP Systems and methods for treating an opioid-induced adverse pharmacodynamic response
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
JP6181770B2 (ja) * 2012-12-31 2017-08-16 ローズ テクノロジーズ ７β−置換６α，１４α−エテノモルフィナンおよび７β−置換６α，１４α−エタノモルフィナンを調製するための方法
TN2015000493A1 (en) 2013-06-04 2017-04-06 Lts Lohmann Therapie Systeme Ag Transdermal delivery system
CN103408553B (zh) * 2013-08-20 2016-02-03 宜昌人福药业有限责任公司 一种氢吗啡酮酸式盐的精制工艺
US8846923B1 (en) * 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
CA2977732C (en) * 2015-03-10 2021-02-23 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine

Also Published As

Publication number Publication date
WO2016142877A1 (en) 2016-09-15
CA2977732C (en) 2021-02-23
JP2020033359A (ja) 2020-03-05
TWI699367B (zh) 2020-07-21
US20170197975A1 (en) 2017-07-13
AR103902A1 (es) 2017-06-14
JP6660399B2 (ja) 2020-03-11
US20210046066A1 (en) 2021-02-18
CN107660207B (zh) 2020-09-29
IL254384A0 (en) 2017-11-30
US9926329B2 (en) 2018-03-27
CA3104099A1 (en) 2016-09-15
CO2017009130A2 (es) 2017-11-21
EA201792014A1 (ru) 2018-01-31
SG11201707350TA (en) 2017-10-30
US10835528B2 (en) 2020-11-17
US10406152B2 (en) 2019-09-10
CN107660207A (zh) 2018-02-02
KR20170137738A (ko) 2017-12-13
MA45902A (fr) 2019-06-19
TW202037597A (zh) 2020-10-16
MX2017011606A (es) 2017-10-26
US10874662B2 (en) 2020-12-29
US20180235955A1 (en) 2018-08-23
JP2018507882A (ja) 2018-03-22
AU2016230750B2 (en) 2019-05-30
AU2019203308A1 (en) 2019-05-30
NZ735736A (en) 2019-02-22
EP3283490A1 (en) 2018-02-21
US20190314364A1 (en) 2019-10-17
TW201639856A (zh) 2016-11-16
US20180162866A1 (en) 2018-06-14
KR20200045010A (ko) 2020-04-29
CA2977732A1 (en) 2016-09-15
US20190298713A1 (en) 2019-10-03
PH12017501641A1 (en) 2018-02-12
AU2016230750A1 (en) 2017-10-12
US10278967B2 (en) 2019-05-07

Similar Documents

Publication Publication Date Title
BR112017019357A2 (pt) sal acetato de buprenorfina e métodos para preparar buprenorfina
HK1231377A1 (zh) 包含喹啉衍生物或其鹽的藥物組合物及其製備方法
CO2017012893A2 (es) Composiciones farmacéuticas que comprenden péptidos neo-antígenos o una sal de los mismos y métodos para preparar las mismas
EA201890123A1 (ru) Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их
BR112016015365A8 (pt) composto, composição farmacêutica e uso de um composto
UA118380C2 (uk) Заміщені сполуки дигідроізохінолінону
CO2017003955A2 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
MX2018005520A (es) Metodos para preparacion de acido obeticolico y derivados de los mismos.
EA201490756A1 (ru) Разагилина цитрамид
EA201790650A1 (ru) Лекарственная форма и способы применения абиратерона ацетата
BR112017009471A2 (pt) síntese de copanlisib e seu sal de di-hidrocloreto.
EP3502103A4 (en) CRYSTALLINE FORM, TYPE OF SALT OF A SUBSTITUTED 2-HYDRO-PYRAZOLE DERIVATIVE AND PREPARATION METHOD THEREOF
CL2015002712A1 (es) Cristales de laquinimod sódico y proceso para la preparación de ellos
EP3263573A4 (en) Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης
EP3530650A4 (en) CRYSTALLINE FORM OF (R) -4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE, PRODUCTION METHOD THEREFOR, AND USE THEREOF
EP3377049A4 (en) CRYSTALLINE FORMS OF TAPENTADOL SALTS AND METHOD FOR THE PRODUCTION THEREOF
EP3176173A4 (en) Crystalline free bases of c-met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof
BR112017008867A2 (pt) inibidores de proteína quinases
EP3564224A3 (en) Crystalline form of vortioxetine hydrobromide as antidepressant drug
EP3150624A4 (en) Crystal of cyclic peptide compound, preparation method for same, and uses thereof
HUE062000T2 (hu) BCL-2 inhibitor új sója, vonatkozó kristályforma, ezek elõállítási eljárása és ezeket tartalmazó gyógyszerkészítmények
MX2019003684A (es) Formas cristalinas de un derivado de acido biliar.
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
MX2016009667A (es) Forma cristalina alfa del compuesto a monobenzoato y método de preparación de la misma y composición farmacéutica que comprende la misma.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2661 DE 04-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.